JALAL PJ, URBANOWICZ RA, HORNCASTLE E, PATHAK M, GODDARD C, SAEED A, MASON CP, BALL JK, IRVING WL, MCCLURE CP, KING BJ and TARR AW, 2019. Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses. Journal of medical microbiology. 68(4), 642-648 HARRISON GI, MURRAY K, GORE R, LEE P, SREEDHARAN A, RICHARDSON P, HUGHES AJ, WISELKA M, GELSON W, UNITT E, RATCLIFF K, ORTON A, TRINDER K, SIMPSON C, RYDER SD, OELBAUM S, FOSTER GR, CHRISTIAN A, SMITH S, THOMSON BJ, REYNOLDS R, HARRIS M, HICKMAN M and IRVING WL, 2019. The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction. 114(6), BRADLEY C, SCOTT RA, COX E, PALANIYAPPAN N, THOMSON BJ, RYDER SD, IRVING WL, AITHAL GP, GUHA IN and FRANCIS S, 2019. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. Eur Radiol. 29(6), MODIN, LINE, ARSHAD, ADAM, WILKES, BRYONY, BENSELIN, JENNIFER, LLOYD, CARLA, IRVING, WILLIAM L. and KELLY, DEIRDRE A., 2019. Epidemiology and natural history of hepatitis C virus infection among children and young people JOURNAL OF HEPATOLOGY. 70(3), 371-378 EL SHARKAWY, RASHA, BAYOUMI, ALI, METWALLY, MAYADA, MANGIA, ALESSANDRA, BERG, THOMAS, ROMERO-GOMEZ, MANUEL, ABATE, MARIA LORENA, IRVING, WILLIAM L., SHERIDAN, DAVID, DORE, GREGORY J., SPENGLER, ULRICH, LAMPERTICO, PIETRO, BUGIANESI, ELISABETTA, WELTMAN, MARTIN, MOLLISON, LINDSAY, CHENG, WENDY, RIORDAN, STEPHEN, SANTORO, ROSANNA, GALLEGO-DURAN, ROCIO, FISCHER, JANETT, NATTERMANN, JACOB, D'AMBROSIO, ROBERTA, MCLEOD, DUNCAN, POWELL, ELIZABETH, LATCHOUMANIN, OLIVIER, THABET, KHALED, NAJIM, MUSTAFA A. M., DOUGLAS, MARK W., LIDDLE, CHRISTOPHER, QIAO, LIANG, GEORGE, JACOB, ESLAM, MOHAMMED, WHITE, ROSE, ROJAS, ANGELA, BASSENDINE, MARGARET, ROSSO, CHIARA, MEZZABOTTA, LAVINIA, LEUNG, REYNOLD, MALIK, BARBARA, MATTHEWS, GAIL, GREBELY, JASON, FRAGOMELI, VINCENZO and JONSSON, JULIE R., 2019. A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-beta 1 dependent mechanisms SCIENTIFIC REPORTS. 9, JACK, KATHRYN, LINSLEY, PAUL, THOMSON, BRIAN and IRVING, WILLIAM, 2019. Hepatitis C virus risk factors and test uptake in an English prison JOURNAL OF HEPATOLOGY. 70, E498-E498 ATHWAL, VARINDER, PRITCHETT, JAMES, SCOTT, JENNIFER, MARTIN, KATHERINE, IRVING, WILLIAM, GUHA, NEIL, HANLEY, NEIL and HANLEY, KAREN PIPER, 2019. SOX9 regulates extracellular matrix proteins in liver fibrosis that correlate with severity of fibrosis JOURNAL OF HEPATOLOGY. 70, E57-E57 WING, PETER A. C., JONES, MELERI, CHEUNG, MICHELLE, DASILVA, SAMPATH, BAMFORD, CONNOR, LEE, WING-YIU JASON, ARANDAY-CORTES, ELIHU, FILIPE, ANA DA SILVA, MCLAUCHLAN, JOHN, SMITH, DAVID, IRVING, WILLIAM, CUNNINGHAM, MORVEN, ANSARI, AZIM, BARNES, ELEANOR and FOSTER, GRAHAM R., 2019. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir GASTROENTEROLOGY. 157(3), 692-+ MECCI, ALI JIBRAN, KEMOS, POLYCHRONIS, LEEN, CLIFFORD, LAWSON, ADAM, RICHARDSON, PAUL, KHAKOO, SALIM I., AGARWAL, KOSH, MUTIMER, DAVID, ROSENBERG, WILLIAM M., FOSTER, GRAHAM R., IRVING, WILLIAM L., AGARWAL, K., ALDERSLEY, M., ALI, A., ARAVAMUTHAN, S., ASPINALL, R., BARNES, E., BROWN, A., CH'NG, C., CORLESS, L., CRAMP, M., FOSTER, G. R., FOXTON, M., GORARD, D., GORDON, F., LAWSON, A., LEEN, C., MOREEA, S., MUTIMER, D., RICHARDSON, P., ROSENBERG, W. R., RYDER, S. D., STONE, B., USTIANOWSKI, A. and VERMA, S., 2019. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 50(2), 204-214
PEDERGNANA, VINCENT, IRVING, WILLIAM L., BARNES, ELEANOR, MCLAUCHLAN, JOHN and SPENCER, CHRIS C. A., 2019. Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 39(10), 642-649 MACKEN, LUCIA, GELSON, WILLIAM, PRIEST, MATTHEW, ABOUDA, GEORGE, BARCLAY, STEPHEN, FRASER, ANDREW, HEALY, BRENDAN, IRVING, WILL and VERMA, SUMITA, 2019. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort JOURNAL OF MEDICAL VIROLOGY. 91(11), 1979-1988 ATHWAL, VARINDER S., PRITCHETT, JAMES, MARTIN, KATHERINE, LLEWELLYN, JESSICA, SCOTT, JENNIFER, HARVEY, EMMA, ZAITOUN, ABED M., MULLAN, AOIBHEANN F., ZEEF, LEO A. H., FRIEDMAN, SCOTT L., IRVING, WILLIAM L., HANLEY, NEIL A., GUHA, INDRA N. and HANLEY, KAREN PIPER, 2019. SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis (vol 8, 17905, 2018) SCIENTIFIC REPORTS. 9, ANSARI, M. AZIM, ARANDAY-CORTES, ELIHU, IP, CAMILLA L. C., FILIPE, ANA DA SILVA, LAU, SIU HIN, BAMFORD, CONNOR, BONSALL, DAVID, TREBES, AMY, PIAZZA, PAOLO, SREENU, VATTIPALLY, COWTON, VANESSA M., BALL, J., BARNES, E., BURGESS, G., COOKE, G., DILLON, J., FOSTER, G., GORE, C., GUHA, N., HALFORD, R., HOLMES, C., HUDSON, E., HUTCHINSON, S., IRVING, W., KHAKOO, S., KLENERMAN, P., MARTIN, N., MBISA, T., MCKEATING, J., MCLAUCHLAN, J., MINERS, A., MURRAY, A., SHAW, P., SIMMONDS, P., SMITH, S., SPENCER, C., THOMSON, E., TROKE, P., VICKERMAN, P., ZITZMANN, N., HUDSON, EMMA, BOWDEN, RORY, PATEL, ARVIND H., FOSTER, GRAHAM R., IRVING, WILLIAM L., AGARWAL, KOSH, THOMSON, EMMA C., SIMMONDS, PETER, KLENERMAN, PAUL, HOLMES, CHRIS, BARNES, ELEANOR, SPENCER, CHRIS C. A., MCLAUCHLAN, JOHN and PEDERGNANA, VINCENT, 2019. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus ELIFE. 8, KENDALL TJ, DOLMAN GE, DUFF CM, PAISH EC, ZAITOUN A, IRVING W, FALLOWFIELD JA and GUHA IN, 2018. Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease. Histopathology. (In Press.)
ABO-ZEID Y, URBANOWICZ RA, THOMSON BJ, IRVING WL, TARR AW and GARNETT MC, 2018. Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy? Int J Pharm. 547(1-2), 572-581 HARRIS M, BONNINGTON O, HICKMAN M, IRVING WL and HEPCATT TEAM, 2018. Understanding hepatitis C intervention success-Qualitative findings from the HepCATT study. J Viral Hepat. 25(7), BAGASI, ARWA A., KHANDAKER, TASNEEM, CLARK, GEMMA, AKAGHA, TERRY, BALL, JONATHAN K., IRVING, WILLIAM L. and MCCLURE, C. PATRICK, 2018. Trichodysplasia Spinulosa Polyomavirus in Respiratory Tract of Immunocompromised Child EMERGING INFECTIOUS DISEASES. 24(9), 1744-1746 MURRAY, ANDREA, MACDONALD, ISABEL, WELBERRY, CHRISTOPHER, MCELVEEN, JANE, PARSY-KOWALSKA, CELINE, ALLEN, JARED, REYNOLDS, CHRISTOPHER, HEALEY, GRAHAM, PEEK, LAURA, IRVING, WILLIAM and HAMILTON-FAIRLEY, GEOFFREY, 2018. Improvement in HCC Risk Stratification Following Positive Imaging for Liver Nodules By Application of a Blood Biomarker Test HEPATOLOGY. 68, 509A-509A
ATHWAL, VARINDER S., PRITCHETT, JAMES, MARTIN, KATHERINE, LLEWELLYN, JESSICA, SCOTT, JENNIFER, HARVEY, EMMA, ZAITOUN, ABED M., MULLAN, AOIBHEANN F., ZEEF, LEO A. H., FRIEDMAN, SCOTT L., IRVING, WILLIAM L., HANLEY, NEIL A., GUHA, INDRA N. and HANLEY, KAREN PIPER, 2018. SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis SCIENTIFIC REPORTS. 8, TOYODA, H., BERHANE, S., DE GROOT, E., TADA, T., KUMADA, T., IRVING, W. and JOHNSON, P., 2018. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection JOURNAL OF HEPATOLOGY. 68, S530-S530 SCOTT, R., BRADLEY, C., PALANIYAPPAN, N., RYDER, S., AITHAL, G., IRVING, W., FRANCIS, S. and GUHA, N., 2018. Direct acting anti-viral treatment for hepatitis C results in a rapid reduction in MRI measures of hepatic microstructure JOURNAL OF HEPATOLOGY. 68, S545-S546 LLIBRE A, SHIMAKAWA Y, MOTTEZ E, AINSWORTH S, BUIVAN TP, FIRTH R, HARRISON E, ROSENBERG AR, MERITET JF, FONTANET A, CASTAN P, MADEJÓN A, LAVERICK M, GLASS A, VIANA R, POL S, MCCLURE CP, IRVING WL, MIELE G, ALBERT ML and DUFFY D, 2018. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut. 67(11), 2017-2024 SIMMONS, R., IRELAND, G., IRVING, W., HICKMAN, M., SABIN, C., IJAZ, S., RAMSAY, M., LATTIMORE, S. and MANDAL, S., 2018. Establishing the cascade of care for hepatitis C in Englandbenchmarking to monitor impact of direct acting antivirals JOURNAL OF VIRAL HEPATITIS. 25(5), 482-490 MANOUCHEHRINIA, ALI, TANASESCU, RADU, KAREEM, HUNER, JERCA, OLTITA P., JABEEN, FOUZIA, SHAFEI, RACHELLE, BREUER, JUDITH, NEAL, KEITH, IRVING, WILLIAM and CONSTANTINESCU, CRIS S., 2017. Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis JOURNAL OF NEUROVIROLOGY. 23(6), 839-844 FILIPE, ANA DA SILVA, SREENU, VATTIPALLY, HUGHES, JOSEPH, ARANDAY-CORTES, ELIHU, IRVING, WILLIAM L., FOSTER, GRAHAM R., AGARWAL, KOSH, ROSENBERG, WILLIAM, MACDONALD, DOUGLAS, RICHARDSON, PAUL, ALDERSLEY, MARK A., WISELKA, MARTIN, USTIANOWSKI, ANDREW, MCLAUCHLAN, JOHN and THOMSON, EMMA C., 2017. Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries JOURNAL OF HEPATOLOGY. 67(6), 1348-1350
MCLAUCHLAN, J., INNES, H., DILLON, J. F., FOSTER, G., HOLTHAM, E., MCDONALD, S., WILKES, B., HUTCHINSON, S. J. and IRVING, W. L., 2017. Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 46(5), 1391-+ YOUNG J, WEIS N, HOFER H, IRVING W, WEILAND O, GIOSTRA E, PASCASIO JM, CASTELLS L, PRIETO M, POSTEMA R, LEFEVRE C, EVANS D, BUCHER HC and CALLEJA JL, 2017. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. BMC infectious diseases. 17(1), 45 ESLAM M, MCLEOD D, KELAENG KS, MANGIA A, BERG T, THABET K, IRVING WL, DORE GJ, SHERIDAN D, GRØNBÆK H, ABATE ML, HARTMANN R, BUGIANESI E, SPENGLER U, ROJAS A, BOOTH DR, WELTMAN M, MOLLISON L, CHENG W, RIORDAN S, MAHAJAN H, FISCHER J, NATTERMANN J, DOUGLAS MW, LIDDLE C, POWELL E, ROMERO-GOMEZ M, GEORGE J and , 2017. IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature genetics. 49(5), 795-800 MANOUCHEHRINIA A, TANASESCU R, KAREEM H, JERCA OP, JABEEN F, SHAFEI R, BREUER J, NEAL K, IRVING W and CONSTANTINESCU CS, 2017. Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of neurovirology. 23(6), 839-844 ESLAM M, MANGIA A, BERG T, CHAN HL, IRVING WL, DORE GJ, ABATE ML, BUGIANESI E, ADAMS LA, NAJIM MA, MIELE L, WELTMAN M, MOLLISON L, CHENG W, RIORDAN S, FISCHER J, ROMERO-GOMEZ M, SPENGLER U, NATTERMANN J, RAHME A, SHERIDAN D, BOOTH DR, MCLEOD D, POWELL E, LIDDLE C, DOUGLAS MW, VAN DER POORTEN D, GEORGE J and , 2016. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology (Baltimore, Md.). 64(1), 34-46 FOSTER GR, IRVING WL, CHEUNG MC, WALKER AJ, HUDSON BE, VERMA S, MCLAUCHLAN J, MUTIMER DJ, BROWN A, GELSON WT, MACDONALD DC, AGARWAL K and , 2016. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of hepatology. 64(6), 1224-31 MARTIN NK, VICKERMAN P, BREW IF, WILLIAMSON J, MINERS A, IRVING WL, SAKSENA S, HUTCHINSON SJ, MANDAL S, O'MOORE E and HICKMAN M, 2016. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (Baltimore, Md.). 63(6), 1796-808 CHEUNG MC, WALKER AJ, HUDSON BE, VERMA S, MCLAUCHLAN J, MUTIMER DJ, BROWN A, GELSON WT, MACDONALD DC, AGARWAL K, FOSTER GR, IRVING WL and , 2016. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of hepatology. 65(4), 741-7 ROBERTS K, MACLEOD J, METCALFE C, SIMON J, HORWOOD J, HOLLINGWORTH W, MARLOWE S, GORDON FH, MUIR P, COLEMAN B, VICKERMAN P, HARRISON GI, WALDRON CA, IRVING W and HICKMAN M, 2016. Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial. Trials. 17, 366 THABET K, ASIMAKOPOULOS A, SHOJAEI M, ROMERO-GOMEZ M, MANGIA A, IRVING WL, BERG T, DORE GJ, GRØNBÆK H, SHERIDAN D, ABATE ML, BUGIANESI E, WELTMAN M, MOLLISON L, CHENG W, RIORDAN S, FISCHER J, SPENGLER U, NATTERMANN J, WAHID A, ROJAS A, WHITE R, DOUGLAS MW, MCLEOD D, POWELL E, LIDDLE C, VAN DER POORTEN D, GEORGE J, ESLAM M and , 2016. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature communications. 7, 12757 IRVING, W. L., 2016. Viral Oncogenesis and Hepatocellular Carcinoma JOURNAL OF PATHOLOGY. 240, 10-10
CONSTANTINESCUS, CRIS, MANOUCHEHRINIA, ALI, TANASESCU, RADU, KAREEM, HUNER, JERCA, OLTITA and IRVING, WILLIAM, 2016. The Prevalence of a History of Prior VZV/HZV Infection in MS: A Survey Study with Serological Validation Sub-Study NEUROLOGY. 86,
LLEWELLYN, ALEXIS, SIMMONDS, MARK, IRVING, WILL L, BRUNTON, GINNY and SOWDEN, AMANDA J, 2016. Antiretroviral therapy and liver disease progression in HIV and hepatitis C co-infected patients: a systematic review and meta-analysis. Hepatology, medicine and policy. 1, 10
SEVRAIN D, DUBREUIL M, DOLMAN GE, ZAITOUN A, IRVING W, GUHA IN, ODIN C and LE GRAND Y, 2015. Evaluation of area-based collagen scoring by nonlinear microscopy in chronic hepatitis C-induced liver fibrosis. Biomedical optics express. 6(4), 1209-18 URBANOWICZ, R. A., MCCLURE, C. P., BROWN, R. J., TSOLERIDIS, T., PERSSON, M. A., KREY, T., IRVING, W. L., BALL, J. K. and TARR, A. W., 2015. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance: J Virol J Virol. 90(7), 3288-301 ESLAM M, HASHEM AM, ROMERO-GOMEZ M, BERG T, DORE GJ, MANGIA A, CHAN HL, IRVING WL, SHERIDAN D, ABATE ML, ADAMS LA, WELTMAN M, BUGIANESI E, SPENGLER U, SHAKER O, FISCHER J, MOLLISON L, CHENG W, NATTERMANN J, RIORDAN S, MIELE L, KELAENG KS, AMPUERO J, AHLENSTIEL G, MCLEOD D, POWELL E, LIDDLE C, DOUGLAS MW, BOOTH DR, GEORGE J and , 2015. FibroGENE: A gene-based model for staging liver fibrosis. Journal of hepatology. 64(2), 390-8 HULLEGIE SJ, ARENDS JE, RIJNDERS BJ, IRVING WL, SALMON D, PRINS M, WENSING AM, KLENERMAN P, LEBLEBICIOGLU H, BOESECKE C, ROCKSTROH JK and HOEPELMAN AI, 2015. Current knowledge and future perspectives on acute hepatitis C infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 21(8), 797.e9-797.e17 IRVING WL, GROTZINGER K, THEODORE D, DEMUTH D, RIZZETTO M, ROUGHLEY A and FORSSEN U, 2015. Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia. Journal of viral hepatitis. 22(5), 511 ESLAM M, HASHEM AM, LEUNG R, ROMERO-GOMEZ M, BERG T, DORE GJ, CHAN HL, IRVING WL, SHERIDAN D, ABATE ML, ADAMS LA, MANGIA A, WELTMAN M, BUGIANESI E, SPENGLER U, SHAKER O, FISCHER J, MOLLISON L, CHENG W, POWELL E, NATTERMANN J, RIORDAN S, MCLEOD D, ARMSTRONG NJ, DOUGLAS MW, LIDDLE C, BOOTH DR, GEORGE J, AHLENSTIEL G and , 2015. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature communications. 6, 6422 MARTIN, N. K., FOSTER, G. R., VILAR, J., RYDER, S., CRAMP, M. E., GORDON, F., DILLON, J. F., CRAINE, N., BUSSE, H., CLEMENTS, A., HUTCHINSON, S. J., USTIANOWSKI, A., RAMSAY, M., GOLDBERG, D. J., IRVING, W., HOPE, V., DE ANGELIS, D., LYONS, M., VICKERMAN, P. and HICKMAN, M., 2015. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact JOURNAL OF VIRAL HEPATITIS. 22(4), 399-408 OZARAS R, CORTI G, RUTA S, LACOMBE K, MONDELLI MU, IRWING WL, PUOTI M, KHALIGHI A, SANTOS ML, HARXHI A, LAZAREVIC I, SORIANO V, GERVAIN J, LEBLEBICIOGLU H, SALMON D, ARENDS JE and , 2015. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 21(11), 1027-32 HAMED MR, BROWN RJP, ZOTHNER C, URBANOWICZ RA, MASON CP, KRARUP A, MCCLURE CP, IRVING WL, BALL JK, HARRIS M, HICKLING TP and TARR AW, 2014. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. Journal of innate immunity. 6(5), 676-84 PATEL K, REMLINGER KS, WALKER TG, LEITNER P, LUCAS JE, GARDNER SD, MCHUTCHISON JG, IRVING W and GUHA IN, 2014. Multiplex Protein Analysis to Determine Fibrosis Stage and Progression in Patients With Chronic Hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. (In Press.)
BACK X,M, LEWSZUK,A, WHITE , JR, COLE, J, SREEDHARAN , A, VAN SANDEN, S, DIELS,J, LAWSON ,A, NEAL, KR, WISELKA, MJ, ITO,T and IRVING,WL, 2014. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1 infected patients who do or do not achieve sustained virological response to therapy. Journal of Viral Hepatitis. 21, 208-215 ARENDS JE, DALTON HR, IRVING W, IZOPET J, HOEPELMAN AIM and SALMON D, 2014. Hepatitis E: an emerging infection with potential serious consequences. Journal of Clinical Virology. 59, 81-88 LATTIMORE S, IRVING W, COLLINS S, PENMAN C and RAMSAY M, 2014. On behalf of the collaboration for the sentinel surveillance of blood-borne virus testing. Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection. Hepatology. 56, 1343-1350
BERRY L and IRVING W, 2014. Predictors of hepatitis C treatment response: what's new Expert Rev Anti Infect Ther. 12(2), 183-191 HAMED MR,, BROWN RJ, ZOTHNER C, URBANOWICZ RA, MASON CP, KRARUP A, MCCLURE CP, IRVING WL, BALL JK HARRIS M, HICKLING TP and TARR AW, 2014. Recombinant human L-ficoin directly neutralizes hepatitis C virus entry. Journal of Innate Immunity. 6, 676-684 RIZZETTO M, GROTZINGER K, THEODORE D, DEMUTH D, IRVING WL, MANNS M, ROUGHLEY A and FORSSEN UM, 2014. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia A retrospective chart review from five European countries. 21(10), 129-134
IRVING W, RUPP D, MCCLURE CP, THAN LM, BALL JK, STEINMANN E, BARTENSCHLAGER R and PIETSCHMANN T, 2014. Development of a high-throughput pyrosequencing assay for investigation of temporal evolution and levels of resistance archiving in the Hepatitis C virus protease gene Antiviral Research. 11oc, 52-59
PATEL K, REMLINGER KS, WALKER TG, LEITNER P, LUCAS JE, GARDNER SD, MCHUTCHISON JG, IRVING W and GUHA N, 2014. Multiplex protein detection for adjacent fibrosis stage and prognostic group classification in chronic hepatitis C infection Clin Gastroenterol Hepatol. 12, 2113-2120
ESLAM M, LEUNG R, MANGIA A, IRVING WL, SHERIDAN D, SPENGLER U, MOLLISON L, CHENG W, DOUGLAS M, BOOTH DR, GEORGE J and AHLENSTIEL G, 2014. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol. 61, 235-241 SUPPIAH V, ARMSTRONG NJ, O'CONNOR JS, BERG T, WELTMAN N, ABATE ML, SPENGLER U, BASSENDINE M, DORE GJ, IRVING WL, POWELL E, NATTERNAM J, MUELLER T, RIORDAN S, STEWART GJ, GEORGE J, BOOTH DR, AHLENSTIEL G and INTERNATIONAL HEPATITIS C GENETICS CONSORTIUM, 2013. CCR5-32 genotype does not improve predictive value of IL-28B polymorphisms for treatment response in chronic HCV infection. Genes & Immunity. (In Press.)
BUCCI C, VON DELFT A, CHRISTIAN A, FLEMMING V, HARRISON G, HALLIDAY J, COLLIER J, MANGANIS C, KLENERMAN P, IRVING WL and BARNES E, 2013. “Favourable” IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy. Journal of General Virology. (In Press.)
TARR, A.W., URBANOWICZ, R.A., JAYARAJ, D., BROWN, R.J.P., MCKEATING, J.A., IRVING, W.L. and BALL, J.K., 2012. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization Journal of Virology. 86(5), 2739-2749 SIMMONS, R., SHARP, C., MCCLURE, C.P., ROHRBACH, J., KOVARI, H., FRANGOU, E., SIMMONDS, P., IRVING, W., RAUCH, A., BOWNESS, P. and KLENERMAN, P., 2012. Parvovirus 4 infection and clinical outcome in high-risk populations Journal of Infectious Diseases. 205(12), 1816-1820 PRITCHETT, J., HARVEY, E., ATHWAL, V., BERRY, A., ROWE, C., OAKLEY, F., MOLES, A., MANN, D.A., BOBOLA, N., SHARROCKS, A.D., THOMSON, B.J., ZAITOUN, A.M., IRVING. W.L., GUHA, I.N., HANLEY, N.A. and HANLEY, K.P., 2012. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans Hepatology. 56(3), 1108-1116 SMITH KR, SUPPIAH V, O'CONNOR K, BERG T, WELTMAN M, ABATE ML, SPENGLER U, BASSENDINE M, MATHEWS G, IRVING WL, POWELL E, RIORDAN S, AHLENSTIEL G, STEWART GJ, BAHLO M, GEORGE J, BOOTH DR, IHCGC, 2011. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine. 3(8), 57
SUPPIAH, V., GAUDIERI, S., ARMSTRONG, N.J., O'CONNOR, K.S., BERG, T., WELTMAN, N., ABATE, M.L., SPENGLER, U., BASSENDINE, M., DORE, D.J., IRVING, W.L., POWELL, E., HELLARD, M., RIORDAN, S., MATTHEWS, G., SHERIDAN, D., NATTERMANN, J., SMEDILE, A., MÜLLER, T., HAMMOND, E., DUNN, D., NEGRO, F., BOCHUD, P-Y., MALLAL, S., AHLENSTIEL, G., STEWART, G.J., GEORGE, J. and BOOTH, D.R., 2011. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross-sectional study PLoS Medicine. 8(9), e1001092 TARR, A.W., URBANOWICZ, R.A., HAMED, M.R., ALBECKA, A., MCCLURE, C.P., BROWN, R.J.P., IRVING, W.L., DUBUISSON, J. and BALL, J.K., 2011. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype Journal of Virology. 85(9), 4246-4257 WILLIAMS MJ, LANG-LENTON M, ON BEHALF OF THE TRENT HCV STUDY GROUP, 2011. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. Journal of Viral Hepatitis. 18, 17-22 IRVING WL, BROWN RJP., 2010. Acute hepatitis C virus infection: a dynamic – and challenging – concept. Journal of Infectious Diseases. 202, 1765-67
PARKES, J., GUHA, I.N., RODERICK, P., HARRIS, S., CROSS, R., MANOS, M.M., IRVING, W., ZAITOUN, A., WHEATLEY, M., RYDER, S. and ROSENBERG, W., 2010. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C Journal of Viral Hepatitis. 18(1), 23-31 GRISHCHENKO M, GRIEVE R, SWEETING M, DE ANGELIS D, THOMSON BJ, RYDER SD, IRVING W AND THE TRENT HCV STUDY GROUP., 2009. Cost-effectiveness of pegylated interferon and ribavirin for different sub-groups of patients with chronic hepatitis C treated in routine clinical practice. International Journal for Technology Assessment in Health Care. 25, 171-80 WILLIAMS MJ, LAWSON A, NEAL K, RYDER SD, IRVING WL, ON BEHALF OF THE TRENT HCV STUDY GROUP., 2009. Autoantibodies in chronic hepatitis C infection and their association with disease profile. Journal of Viral Hepatitis. 16, 325-31 HAMED, M.R.B., TARR, A.W., MCCLURE, C.P., BALL, J.K., HICKLING, T.P. and IRVING, W.L., 2008. Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease Journal of Viral Hepatitis. 15(5), 339-345 THOMSON, B.J., KWONG, G., RATIB, S., SWEETING, M., RYDER, S.D., DE ANGELIS, D., GRIEVE, R. and IRVING, W.L., 2008. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management Journal of Viral Hepatitis. 15(4), 271-278 IRVING, W.L., SALMON, D., BOUCHER, C. and HOEPELMAN, I.M., 2008. Acute hepatitis C virus infection Eurosurveillance. 13(21), 18879 BRANT,, RAMSAY,, BALOGUN,, BOXALL,, HALE,, HURRELLE,, KALUBA,, KLAPPER,, LEWIS,, PATEL,, PARRY, and IRVING,, 2008. Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations. Journal of viral hepatitis. 871-7
LAWSON A., HAGAN S., RYE K., TAGURI N., RATIB S., ZAITOUN A.M., NEAL K.R., RYDER S.D., IRVING W.L. and TRENT HCV STUDY GROUP, 2007. The natural history of hepatitis C with severe hepatic fibrosis. Journal of Hepatology. 47(1), 37-45 TARR, ALEXANDER W, OWSIANKA, ANIA M, JAYARAJ, DHANYA, BROWN, RICHARD J P, HICKLING, TIMOTHY P, IRVING, WILLIAM L, PATEL, ARVIND H and BALL, JONATHAN K, 2007. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. Journal of General Virology. 88(Pt 11), 2991-3001
SMELLIE WSA, FORTH J, COLEMAN J, IRVING W, DORE PC, HANDLEY G, WILLIAMS DG, GALLOWAY PJ, KERR JG, HERRIOTT R, SPICKETT GP, REYNOLDS TM., 2007. Best practice in primary care pathology: review 6. Journal of Clinical Pathology. 60, 225-234 (In Press.)
BRANT, L J, HURRELLE, M, BALOGUN, M A, KLAPPER, P, AHMAD, F, BOXALL, E, HALE, A, HOLLYOAK, V, IBRAHIM, I B, IRVING, W, MEIGH, R, MUTTON, K J, PATEL, B C, PAVER, W K, PUGH, S, TAYLOR, C, TURNER, A J and R, 2007. Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiology and Infection. 135(3), 417-26 NEAL KR AND THE TRENT HCV STUDY GROUP, 2007. Excess mortality rates in a cohort infected with the hepatitis C virus: a prospective UK study. Gut. 56, 1098-1104
BROWN KS, KEOGH MJ, TAGIURI N, GRAINGE MJ, PRESANIS JS, RYDER SD, IRVING WL, BALL JK, SIM RB, HICKLING TP., 2007. Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clinical and Experimental Immunology. 147, 90-98 (In Press.)
BROWN KS, RYDER SD, IRVING WL, SIM RB, HICKLING TP., 2007. Mannan binding lectin and viral hepatitis. Immunology Letters. 108, 34-44 (In Press.)
SMELLIE, W S A, FORTH, J, SMART, S R S, GALLOWAY, M J, IRVING, W, BAREFORD, D, COLLINSON, P O, KERR, K G, SUMMERFIELD, G, CAREY, P J and MINHAS, RUBIN, 2007. Best practice in primary care pathology: review 7. Journal of Clinical Pathology. 60(5), 458-65 IRVING, W.L., SMITH, S., CATER, R., PUGH, S., NEAL, K.R., COUPLAND, C.A., RYDER, S.D., THOMSON, B.J., PRINGLE, M., BICKNELL, M. and HIPPISLEY-COX J., 2006. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens Journal of Viral Hepatitis. 13(4), 264-271 COUPLAND C, HIPPISLEY-COX J, SMITH S, IRVING W, PRINGLE M, RYDER S, NEIL K, CATER R, THOMSON B, PUGH S, BICKNELL M, BULLOCK D., 2006. General Practice characteristics associated with rates of testing and detection of hepatitis C: Cross sectional study in Nottingham and Derbyshire. British J Gen Practice. 56, 620-623 (In Press.)
DAWES R, HENNIG B, IRVING W, PETROVA S, BOXALL S, WARD V, WALLACE D, MACALLAN D, THURSZ M, HILL A, BODMER W, BEVERLEY PCL, TCHILIAN EZ., 2006. CD45 C77G variant is increased in Hepatitis C and is associated with disease severity. Journal of Medical Genetics. 43, 678-84.
SCOTT BB, EGNER W ON BEHALF OF THE TRENT HEPATITIS C STUDY GROUP., 2006. Does α-1 antitrypsin phenotype PiMZ increase the risk of fibrosis in liver disease due to HCV infection? Eur J Gastroenterol Hepatol. 18, 521-523 SWEETING MJ, DE ANGELIS D, NEAL KR, RAMSAY ME, IRVING WL, WRIGHT M, BRANT L, HARRIS HE, THE TRENT HCV STUDY GROUP AND THE HCV NATIONAL REGISTER STEERING GROUP., 2006. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. Journal of Clinical Epidemiology. 144-152 BROWN RJP, JUTTLA VS, FINNIS R, TARR AW, HEMSLEY S, FLOWER DR, BORROW P, IRVING WL, BALL JK., 2005. Evolutionary dynamics of Hepatitis C virus envelope genes during chronic infection. Journal of General Virology. 86, 1931-1942 MINTON EJ, SMILLIE D, SMITH P, SHIPLEY S, MCKENDRICK MW, GLEESON DC, UNDERWOOD JCE, CANNINGS C, WILSON AG, AND THE TRENT HEPATITIS C STUDY GROUP., 2005. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or –10 genes. Human Immunology. 66, 127-132 WOZNIAK, M.A., ITZHAKI, R.F., FARAGHER, E.B., JAMES, M.W., RYDER, S.D., IRVING, W.L. and TRENT HCV STUDY GROUP, 2002. Apolipoprotein Ε-Ε4 protects against severe liver disease caused by hepatitis C virus Hepatology (Baltimore, Md.). 36(2), 456-463 CURRAN, R., JAMESON, C. L., CRAGGS, J. K., GRABOWSKA, A. M., THOMSON, B. J., ROBINS, A., IRVING, W. L. and BALL, J. K., 2002. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity Journal of General Virology. VOL 83(PART 1), 11-23
SABRY, A. A., SOBH, M. A., IRVING, W. L., GRABOWSKA, A., WAGNER, B. E., FOX, S., KUDESIA, G. and EL NAHAS, A. M., 2002. A comprehensive study of the association between hepatitis C virus and glomerulopathy Nephrology, Dialysis, Transplantation. VOL 17(PART 2), 239-245 SABRY, A. A., SOBH, M. A., SHEAASHAA, H. A., KUDESIA, G., WILD, G., FOX, S., WAGNER, B. E., IRVING, W. L., GRABOWSKA, A. and EL-NAHAS, A. M., 2002. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy Nephrology, Dialysis, Transplantation. VOL 17(PART 11), 1924-1930 IRVING, WILLIAM L, 2002. The role of the virology laboratory in the management of hepatitis C virus infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 25(1), 3-13
GRABOWSKA, A.M., LECHNER, F., KLENERMAN, P., TIGHE, P.J., RYDER, S., BALL, J.K., THOMSON, B.J., IRVING, W.L. and ROBINS, R.A., 2001. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection European Journal of Immunology. 31(8), 2388-2394 CRAGGS, J.K., BALL, J.K., THOMSON, B.J., IRVING, W.L. and GRABOWSKA, A.M., 2001. Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA Journal of Virological Methods. 94(1-2), 111-120 CARONIA, S., BASSENDINE, M. F., BARRY, R., MILLS, P., NAOUMOV, N. V., FOX, R., LOWES, J., HOLLANDERS, D., MURRAY-LYON, I. and IRVING, W. L., 2001. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study Journal of Hepatology. VOL 35(NUMBER 4), 512-516 A MOHSEN AND THE TRENT HEPATITIS C VIRUS STUDY GROUP, 2001. The epidemiology of hepatitis C in a UK Health Regional population of 5.12 million. Gut. 48, 707-713
IRVING, W.L., JAMES, D.K., STEPHENSON, T.J., LAING, P., JAMESON, C., OXFORD, J.S., CHAKRAVERTY, P., BROWN, D.W., BOON, A.C. and ZAMBON, M.C., 2000. Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study British Journal of Obstetrics and Gynaecology. 107(10), 1282-1289 GRABOWSKA, A. M., JENNINGS, R., LAING, P., DARSLEY, M., JAMESON, C. L., SWIFT, L. and IRVING, W. L., 2000. Immunisation with Phage Displaying Peptides Representing Single Epitopes of the Glycoprotein G Can Give Rise to Partial Protective Immunity to HSV-2 Virology. VOL 269(PART 1), 47-53 IRVING, W. L., BALL, J. K., BERRIDGE, S., CURRAN, R., GRABOUSKA, A. M., JAMESON, C. L., NEAL, K. R., RYDER, S. D. and THOMSON, B. J., 1999. TT Virus Infection in Patients with Hepatitis C: Frequency. Persistence, and Sequence Heterogeneity Journal of Infectious Diseases. VOL 180(NUMBER 1), 27-34 GRABOWSKA, A., JAMESON, C., LAING, P., JEANSSON, S., SJOEGREN-JANSSON, E., TAYLOR, J., CUNNINGHAM, A. and IRVING, W. L., 1999. Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1 Journal of General Virology. VOL 80(NUMBER 7), 1789-1798
BALL, J K, ROWE, T, CURRAN, R, IRVING, W L, BEARDS, G M, SONTAG, G, YOULE, M, MOYLE, G and PILLAY, D, 1999. Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy. Sexually Transmitted Infections. 75(5), 337-9 BALL, J K, CURRAN, R, BERRIDGE, S, GRABOWSKA, A M, JAMESON, C L, THOMSON, B J, IRVING, W L and SHARP, P M, 1999. TT virus sequence heterogeneity in vivo: evidence for co-infection with multiple genetic types. Journal of General Virology. 80 ( Pt 7), 1759-68 CULL, G. M., TIMMS, J. M., HAYNES, A. P., RUSSELL, N. H., IRVING, W. L., BALL, J. K. and THOMSON, B. J., 1998. Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8 British Journal of Haematology. VOL 100(NUMBER 4), 793 HOLLINGSWORTH, R. C., JAMESON, C. L., MINTON, J. E., CROWE, M., CURRAN, R., ROWE, T., GRABOWSKA, A. M., PILLAY, D., IRVING, W. L. and BALL, J. K., 1998. GBV-C/HGV Coinfection in HIV-1-Positive Men: Frequent Detection of Viral RNA in Blood Plasma But Absence From Seminal Fluid Plasma Journal of Medical Virology. VOL 56(NUMBER 4), 321-326 MINTON, E J, SMILLIE, D, NEAL, K R, IRVING, W L, UNDERWOOD, J C and JAMES, V, 1998. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. Journal of Infectious Diseases. 178(1), 39-44
EDWARDS, S, ZVARTAU, M, CLARKE, H, IRVING, W and BLUMHARDT, L D, 1998. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 64(6), 736-41 TONG, C Y, HOLLINGSWORTH, R C, WILLIAMS, H, IRVING, W L and GILMORE, I T, 1998. Effect of genotypes on the quantification of hepatitis C virus (HCV) RNA in clinical samples using the Amplicor HCV Monitor Test and the Quantiplex HCV RNA 2.0 assay (bDNA). Journal of Medical Virology. 55(3), 191-6 ESKITURK,A., DAVIES,J., IRVING,W.L., MINTON,E.J. and IQBAL,A., 1998. Hepatitis G virus infection in lymphoma patients and in blood donors Journal of Clinical Pathology. 51(9), 676-678 DAVISON, S M, SKIDMORE, S J, COLLINGHAM, K E, IRVING, W L, HUBSCHER, S G and KELLY, D A, 1998. Chronic hepatitis in children after liver transplantation: role of hepatitis C virus and hepatitis G virus infections. Journal of Hepatology. 28(5), 764-70 HOLLINGSWORTH, R. C., SILLEKENS, P., VAN DEURSEN, P., NEAL, K. R. and IRVING, W. L., 1996. Serum HCV RNA levels assessed by quantitative NASBA[R]: stability of viral load over time, and lack of correlation with liver disease Journal of Hepatology. VOL 25(NUMBER 3), 301-306